Beacon Therapeutics Announces Positive 3-Month Data from Phase 2 DAWN Trial of laru-zova (AGTC-501) in Patients with X-Linked Retinitis Pigmentosa (XLRP)

To date, laru-zova has been well-tolerated by all participants in the Phase 2 DAWN study. Data show promising early improvements in low luminance visual acuity (LLVA), a critical measure of visual function. Data build confidence in laru-zova as a potential treatment for patients with XLRP….

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.